Stay updated on Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial

Sign up to get notified when there's something new on the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.3%
    Check dated 2025-04-30T16:59:51.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The date has been updated from January 14, 2025, to April 23, 2025.
    Difference
    0.7%
    Check dated 2025-04-23T15:40:23.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.4 to v2.15.0, indicating a revision in the content. The phrase 'Here’s how you know' has been removed and replaced with the same phrase, suggesting a possible formatting or presentation change rather than a substantive content update.
    Difference
    1.0%
    Check dated 2025-04-16T12:58:59.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 14, 2025.
    Difference
    1.0%
    Check dated 2025-04-09T05:54:51.000Z thumbnail image
  6. Check
    79 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    5%
    Check dated 2025-02-24T20:28:43.000Z thumbnail image
  7. Check
    94 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    6%
    Check dated 2025-02-10T09:40:57.000Z thumbnail image

Stay in the know with updates to Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ivosidenib+Venetoclax±Azacitidine in IDH1 Mutated Blood Cancers Clinical Trial page.